What People Think
 |
 |
29% For, 71% Against
Take Action
| Vote on this Bill | |
  |
For |
  |
Against |
| Speak Out | |
  |
Comment on this Bill |
  |
Alert Your Friends and Colleagues |
  |
Write Your Representative in Congress |
| Save & Share | |
 |
del.icio.us |
 |
Digg |
 |
|
 |
|
 |
|
 |
Yahoo! |
S. 1695, The Biologics Price Competition and Innovation Act of 2007
You must be logged in to your WashingtonWatch.com account in order to edit this wiki page.
(Learn how to edit the WashingtonWatch.com wiki.)
Don't have an account? Register for your free account now!
Cost per :
Learn More
Trackback URL: http://www.washingtonwatch.com/bills/trackback/110_SN_1695.html
RSS Feeds for This Bill
Keep yourself updated on user contributions and debates about this bill! (Learn more about RSS.)
Visitor Comments
Ryan
One of the reasons why generic drugs are good for the consumer is that the companies don't have to do clinical trials. There are already methods of characterization which are acceptable for showing biological equivalence. By forcing follow-on biologic producers to do clinical trials (which they don't have to do for chemical, small-molecule drugs), this will increase cost to the consumer and reduce the level of treatment available to those who need it most.
m
Clinical trials are necessary for biosimilars though because regular generics (small molecules) have no risk of triggering an immune system reaction. The science is different for the two types of generics and thus clinical requirements are different